All In Biotech

Drug Trial Radar · NCT02323126

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Feb 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

64

Actual

Start

Feb 9, 2015

Primary completion

Sep 23, 2019

Study completion Feb 5, 2021

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the efficacy and safety of nivolumab in combination with EGF816 and of nivolumab in combination with INC280 in previously treated NSCLC patients

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • EGF816Drug

    EGF816 150 mg once daily (QD) administered orally as a capsule

  • INC280Drug

    INC280 400 mg twice daily (BID) administered orally as a tablet

  • NivolumabDrug

    Nivolumab 3 mg/kg every 2 weeks (Q2W) administered by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Rate at 6 Months Per RECIST v1.1Time frame: 6 months

Locations

13 sites in 8 countries. Site status is shown where the registry gives one.

  • University of Texas MD Anderson Cancer Center Thoractic Head/Neck Med.Onc(2)

    Houston, Texas

  • Novartis Investigative Site

    Camperdown, New South Wales, Australia

  • Novartis Investigative Site

    Chermside, Queensland, Australia

  • Novartis Investigative Site

    La Tronche, France

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Perugia, PG, Italy

  • Novartis Investigative Site

    Aviano, PN, Italy

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Málaga, Andalusia, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Alicante, Valencia, Spain

  • Novartis Investigative Site

    Chur, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.